Regeneron Pharmaceuticals News and Activities
Presence
Regeneron Pharmaceuticals is a leading biotechnology company that develops and commercializes pharmaceutical products primarily for the treatment of serious medical conditions. Their products primarily serve patients in need of advanced treatments for conditions such as age-related macular degeneration, asthma, cancer, and cardiovascular diseases.
Regeneron Pharmaceuticals products and services overview:
- Ophthalmology
- Oncology
- Cardiovascular
- Respiratory
2024 Revenue: Approximately $10 billion
Employees: 9,500
Regeneron Pharmaceuticals is one of the...
- Forbes Global 2000 (#431);
- Fortune 500 (#311);
- Global Fortune 500 (#306);
- Nasdaq 100;
- Russell 3000;
- S&P 500;
- TOB Iconic 10,000.
Regeneron Pharmaceuticals is a company listed under the stock ticker REGN (US).
They are in:
- Pharmaceuticals50%
- Biotechnology50%
Acquisition, funding and merger involving Regeneron Pharmaceuticals.
- Regeneron Pharmaceuticals has announced the acquisition of 23andMe (posted on May 20 2025).
Executives
View the org chart displaying its 101 main executives
Most searched biographies at Regeneron Pharmaceuticals
- Leonard Schleifer, President, Chief Executive Officer, Director
- Bonnie Bassler, Chairman of the Board
- Huda Zoghbi, Director
Create your alert
to follow the executive moves at Regeneron Pharmaceuticals.
Pharmaceuticals
Regeneron Pharmaceuticals has 1,837 competitors including Pfizer (United States (USA)), Johnson & Johnson (United States (USA)) and Sanofi (France).
Popular M&A news in Pharmaceuticals
- ESSA Pharma and Xoma have announced they will merge (posted on July 14 2025)..
- Pathos becomes a unicorn with its fundraising of $365 Million. (posted on July 4 2025).
- Vor Biopharma and Incyte have announced they will merge (posted on June 30 2025)..
Popular contacts in Pharmaceuticals
News
Press releases by Regeneron Pharmaceuticals
- CHMP Recommends Approval of Dupixent® (dupilumab) for Children Aged 6 to 11 Years with Severe Atopic Dermatitis | Regeneron Pharmaceuticals Inc.
- https://newsroom.regeneron.com/node/24391/pdf
- https://newsroom.regeneron.com/node/24386/pdf
- Regeneron's Antibody Cocktail REGN-EB3 (Inmazeb®) is First FDA-Approved Treatment for Ebola (Zaire Ebolavirus) | Regeneron Pharmaceuticals Inc.
- Dupixent® (dupilumab) Significantly Reduced Severe Asthma Attacks in Children and is the Only Biologic to Demonstrate Improvement in Children's Lung Function in a Randomized Phase 3 Trial | Regeneron Pharmaceuticals Inc.
- Regeneron to Report Third Quarter 2020 Financial and Operating Results and Host Conference Call and Webcast on November 5, 2020 | Regeneron Pharmaceuticals Inc.
- Regeneron's REGN-COV2 Antibody Cocktail Reduced Viral Levels and Improved Symptoms in Non-Hospitalized COVID-19 Patients | Regeneron Pharmaceuticals Inc.
- Late-breaking ESMO Presentation Shows Libtayo® (cemiplimab) Monotherapy Increases Overall Survival in First-line Advanced Non-small Cell Lung Cancer with PD-L1 Expression of ≥50% | Regeneron Pharmaceuticals Inc.
- Press Releases | Regeneron Pharmaceuticals Inc.
- Positive Pivotal Data for Libtayo® (cemiplimab) Monotherapy in Locally Advanced Basal Cell Carcinoma Featured as a Late-breaking Presentation at ESMO | Regeneron Pharmaceuticals Inc.
- View more press releases Close
Social media about Regeneron Pharmaceuticals
- Regeneron Pharmaceuticals on Wikipedia, Google News & Yahoo Finance
- Regeneron Pharmaceuticals on LinkedIn, Twitter & YouTube
